Table 4 Adverse events associated with artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) treatment in Owando health facilities
From: Malaria burden and anti-malarial drug efficacy in Owando, northern Congo
Adverse events | ASAQ (n/N; %) | AL (n/N; %)a | |||||
|---|---|---|---|---|---|---|---|
Day 1 | Day 2 | Day 3 | Total | Day 1 | Day 2 | Total | |
Asthenia | 4/61; 5.6 | 6/61; 9.8 | 3/59; 5.1 | 13/181; 7.2 | 1/57; 1.8 | 1/56; 1.8 | 2/113; 1.8 |
Vomiting | 3/61; 4.9 | 0/61; 0 | 0/59; 0 | 3/181; 1.6 | 1/57; 1.8 | 0/56; 0 | 1/113; 0.9 |
Headache | 0/61; 0 | 1/61; 1.6 | 0/59; 0 | 1/181; 0.6 | 0/57; 0 | 0/56; 0 | 0/113; 0 |
Urticaria | 0/61; 0 | 1/61; 1.6 | 0/59; 0 | 1/181; 0.6 | 0/57; 0 | 0/56; 0 | 0/113; 0 |
Abdominal pain | 1/61; 1.6 | 1/61; 1.6 | 1/59; 1.7 | 3/181; 1.7 | 0/57; 0 | 0/56; 0 | 0/113; 0 |
Total | 8/61; 13.1 | 9/61; 14.8 | 4/59; 6.8 | 21/181; 11.6†| 2/57; 0.7 | 1/56; 0.4 | 3/113: 2.7†|